Eflapegrastim, a long-acting GCSF, administered the same day as chemotherapy in patients with early-stage breast cancer: Results from a multicenter, open-label, study

Manuel Modiano[1], Omkar Marathe[2], Shanta Chawla[3], Jeffery L. Vacirca[4], Kenneth Crist[5], Howard Franklin[5], Lee Schwartzberg[6]

[1]Arizona Clinical Research Center, Tucson, AZ, USA; [2]The Oncology Institute of Hope and Innovation, Downey, CA, USA; [3]Spectrum Pharmaceuticals, Inc., Irvine, CA, USA; [4]New York Cancer Specialists, East Setauket, NY, USA; [5]Assertio Pharmaceuticals, Inc., Lake Forest, IL, USA; [6]Renown Health Pennington Cancer Institute, Reno, NV, USA

Presenting author: Lee Schwartzberg

References
[illegible]

Acknowledgments and Funding: [illegible]

Disclosures: [illegible]

INTRODUCTION

[illegible]

Figure 1. Structure of Eflapegrastim – Long-acting GCSF



OBJECTIVE

- To evaluate the safety and efficacy of same-day dosing of eflapegrastim in patients with ESBC receiving TC chemotherapy

METHODS

Study Design

[illegible]

Patient population

[illegible]

Study Endpoints

[illegible]

Assessment Schedule

[illegible]

Figure 2. Study Design



RESULTS

Baseline Characteristics

[illegible]

Table 1. Demographics and Baseline Characteristics

	Eflapegrastim
Age, years	
Median (range)	[illegible]
Weight, kg	
Mean (range)	[illegible]
Females, %	100
Race, n (%)	
White or Caucasian	[illegible]
Black or African American	[illegible]
Asian	[illegible]
Other	[illegible]
ECOG, n (%)	
0	[illegible]
1	[illegible]
ANC	
Mean (SD)	[illegible]

[illegible]

Efficacy

[illegible]

Table 2. Efficacy Outcomes in Cycle 1

	Eflapegrastim
[illegible]	[illegible]

Figure 3. Mean ANC Profile for Eflapegrastim in Cycle 1



Safety

[illegible]

Table 3. Treatment-Emergent Adverse Events (TEAEs) of Special Interest Occurring in ≥5% of Patients

[illegible]	[illegible]	[illegible]	[illegible]

CONCLUSION

[illegible]